Topic

Michael Christel is Pharmaceutical Executive and Applied Clinical Trials' Managing Editor. He can be reached at mchristel@mmhgroup.com.

Articles

How an early personal realization in healthcare focus paved path for greater impact.

Same Mission, Altered Course

Michele Meyer is a freelance profile and medical writer. She is based in Houston, Texas.

Saving and transforming as many patients’ lives as possible has been the driving force behind  Beth Seidenberg’s audacious career, where she has excelled as a doctor, researcher, and venture capitalist.

A Dogged Devotion

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

After helping lead Novo Nordisk on a transformational journey from a troubled 2016 to double-digit growth in 2021, Doug Langa, Executive Vice President, Head of North America Operations and President of Novo Nordisk, Inc., is calling on his experience of taking the less conventional and sometimes unexpected routes to success to lead Novo Nordisk into new territory.

Roads Less Traveled

Illinois BIO‘s (iBIO) new chairperson, Horizon Therapeutic‘s Marilyn Vetter, outlines the work she plans to do to expand the state’s existing life sciences ecosystem.

Lighting Up Life Sciences in Illinois

Ted Schroeder, CEO of Nabriva Therapeutics, is passionate in his forward-thinking approach to finding the next generation of anti-infectives, as resistance to least-expensive, tried-and-true therapies continues to grow.

Ethics of Antibiotics

Julian Upton is Pharmaceutical Executive’s European and Online Editor. He can be reached at 

Biohaven CEO Vlad Coric talks to Pharm Exec about NURTEC ODT’s swift and seismic impact on the migraine market.

A Clear-Headed Approach to Migraine: Vlad Coric, Biohaven

Pharm Exec speaks to George Hampton, CEO of Currax, one of the only pharma companies addressing obesity and smoking.

Currax Pharmaceuticals: Targeting Smoking and Obesity

Masahide Goto outlines the world of the Astellas Institute for Regenerative Medicine (AIRM), which serves as the company’s global hub for regenerative medicine and cell therapy research and manufacturing in ophthalmology and other therapeutic areas that have few or no available treatment options. 

Bringing New Solutions into View for Cell and Gene Therapies: Masahide Goto, President, AIRM

Ariel Katz, CEO and co-founder of H1, talks about how to find the right KOL for the right audience at the right time.

Solving a 40-Plus-Year Healthcare Industry Puzzle: Ariel Katz, H1

As emerging technologies are identified, C-suites need to determine how they might be pragmatically deployed as solutions to address their pain points, says IBM‘s Dr. Bernard S. Meyerson.

Executive Profiles